ERBB2 and breast cancer: Several randomized trials have demonstrated adjuvant use of trastuzumab (Herceptin®; Roche, Basel, Switzerland) to have a major and persistent benefit in reducing the risk of distant recurrence and death in patients with HER2-positive BC (3–5).